Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 6/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120979 | 1.00 | CNR2 (0.33) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL29775914 | 0.94 | USP7 (0.34) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL29862847 | 0.92 | DDR1 (0.34) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL29862692 | 0.92 | NSD2 (0.33) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL23136410 | 0.92 | DDR1 (0.34) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL29863107 | 0.91 | DDR1 (0.34) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL29863162 | 0.90 | NSD2 (0.33) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL23121102 | 0.90 | DDR1 (0.34) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL23121105 | 0.90 | DDR1 (0.34) | CNR2CNR1NSD2SLC29A1FGFR1 | |
| SCHEMBL23120994 | 0.90 | CNR2 (0.32) | CNR2CNR1NSD2SLC29A1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013756-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021053617-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |